Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613932 | 0.94 | PARP1 (0.89) | PARP1PIM1CSNK1DHTR6 | |
| SCHEMBL1321187 | 0.93 | PARP1 (1.00) | PARP1PIM1CSNK1DNAMPT | |
| SCHEMBL61115 | 0.91 | PARP1 (0.84) | PARP1PIM1CSNK1DHTR6 | |
| SCHEMBL14336535 | 0.90 | PARP1 (0.81) | PARP1PIM1CSNK1D | |
| SCHEMBL10035768 | 0.89 | PARP1 (0.91) | PARP1PIM1CSNK1DNAMPT | |
| SCHEMBL2682991 | 0.87 | PARP1 (1.00) | PARP1PIM1CSNK1DNAMPT | |
| SCHEMBL2684444 | 0.86 | PARP1 (0.80) | PARP1PIM1CSNK1DNAMPT | |
| SCHEMBL14336601 | 0.86 | PARP1 (0.79) | PARP1PIM1CSNK1D | |
| SCHEMBL14252328 | 0.85 | PARP1 (0.84) | PARP1PIM1CSNK1DNAMPT | |
| SCHEMBL12658579 | 0.83 | PARP1 (0.71) | PARP1PIM1CSNK1DNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883787-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883787-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883787-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130345225-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8470825-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470825-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470825-B2 | Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110092478-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | EISAI INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7820668-B2 | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820668-B2 | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820668-B2 | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP | EISAI INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | MGI GP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | MGI GP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | MGI GP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1841771-A4 | DIAZABENZO[DE]ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | MGI GP INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1841771-A2 | DIAZABENZOÝDE¨ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | MGI GP, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006078711-A2 | DIAZABENZO[DE]ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | MGI GP, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115873-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 745/4885CSNK1D 3002/4885 |
| US-20090028815-A1 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 622/4885CSNK1D 3185/4885 |
| US-20130345225-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 622/4885CSNK1D 3185/4885 |
| US-20110092478-A1 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PARP1 1/4885PIM1 622/4885CSNK1D 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.